Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Shacham

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Medicinal Research Reviews|October 2, 2001
Modeling the 3D structure of GPCRs from sequenceS Shacham, M Topf, N Avisar, et al.
Vitamins and Hormones|May 19, 2001
Mechanism of GnRH receptor signaling on gonadotropin release and gene expression in pituitary gonadotrophsS Shacham, D Harris, H Ben-Shlomo, et al.
British Journal of Cancer|June 20, 2014
KPT-330 has antitumour activity against non-small cell lung cancerH Sun, N Hattori, W Chien, et al.
Leukemia|May 24, 2016
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cellsJ Etchin, A Berezovskaya, A S Conway, et al.
Leukemia|August 1, 2012
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsJ Etchin, Q Sun, A Kentsis, et al.
Leukemia|June 12, 2013
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276J Schmidt, E Braggio, K M Kortuem, et al.
Gynecologic Oncology|December 12, 2019
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignanciesI B Vergote, B Lund, U Peen, et al.
Leukemia|June 22, 2016
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesZ A Hing, H Y J Fung, P Ranganathan, et al.
Leukemia|April 17, 2013
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsY-T Tai, Y Landesman, C Acharya, et al.
Leukemia|July 24, 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG miceJ Etchin, J Montero, A Berezovskaya, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Medicinal Research Reviews|October 2, 2001
Modeling the 3D structure of GPCRs from sequenceS Shacham, M Topf, N Avisar, et al.
Vitamins and Hormones|May 19, 2001
Mechanism of GnRH receptor signaling on gonadotropin release and gene expression in pituitary gonadotrophsS Shacham, D Harris, H Ben-Shlomo, et al.
British Journal of Cancer|June 20, 2014
KPT-330 has antitumour activity against non-small cell lung cancerH Sun, N Hattori, W Chien, et al.
Leukemia|May 24, 2016
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cellsJ Etchin, A Berezovskaya, A S Conway, et al.
Leukemia|August 1, 2012
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsJ Etchin, Q Sun, A Kentsis, et al.
Leukemia|June 12, 2013
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276J Schmidt, E Braggio, K M Kortuem, et al.
Gynecologic Oncology|December 12, 2019
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignanciesI B Vergote, B Lund, U Peen, et al.
Leukemia|June 22, 2016
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesZ A Hing, H Y J Fung, P Ranganathan, et al.
Leukemia|April 17, 2013
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implicationsY-T Tai, Y Landesman, C Acharya, et al.
Leukemia|July 24, 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG miceJ Etchin, J Montero, A Berezovskaya, et al.
Pageof 2